<DOC>
	<DOCNO>NCT00665093</DOCNO>
	<brief_summary>This trial conduct Europe . The aim observational study evaluate glycaemic control patient type 1 2 diabetes use NovoMix® 30 Levemir® normal clinical practice condition .</brief_summary>
	<brief_title>Observational Study Patients Using NovoMix® 30 Levemir® Treatment Type 1 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Levemir® 6 yr NovoMix® 30 18 yr Patients Type 1 Type 2 diabetes , include newly diagnose Current treatment NovoMix® 30 Levemir®</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>